The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Effect of sunitinib (SU) administration on post-treatment survival in patients with metastatic renal cell carcinoma (mRCC) treated on the upfront randomized phase III trial of sunitinib or interferon alfa (IFN).
K. B. Blagoev
No relevant relationships to disclose
J. Wilkerson
No relevant relationships to disclose
W. D. Stein
No relevant relationships to disclose
R. J. Motzer
Research Funding - Pfizer
S. E. Bates
No relevant relationships to disclose
A. T. Fojo
No relevant relationships to disclose